These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 36212775)

  • 1. Oncolytic virus-mediated p53 overexpression promotes immunogenic cell death and efficacy of PD-1 blockade in pancreatic cancer.
    Araki H; Tazawa H; Kanaya N; Kajiwara Y; Yamada M; Hashimoto M; Kikuchi S; Kuroda S; Yoshida R; Umeda Y; Urata Y; Kagawa S; Fujiwara T
    Mol Ther Oncolytics; 2022 Dec; 27():3-13. PubMed ID: 36212775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancer.
    Kajiwara Y; Tazawa H; Yamada M; Kanaya N; Fushimi T; Kikuchi S; Kuroda S; Ohara T; Noma K; Yoshida R; Umeda Y; Urata Y; Kagawa S; Fujiwara T
    Cancer Immunol Immunother; 2023 May; 72(5):1285-1300. PubMed ID: 36436021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is oncolytic adenoviral-mediated immunotherapy through p53-overexpression the solution to refractory pancreatic ductal adenocarcinoma?
    Harriss LJA; Stevens L; Rayner CJ; Simpson G; Annels NE; Frampton AE
    Expert Rev Gastroenterol Hepatol; 2024 Jun; 18(6):223-226. PubMed ID: 38818792
    [No Abstract]   [Full Text] [Related]  

  • 4. Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody.
    Kanaya N; Kuroda S; Kakiuchi Y; Kumon K; Tsumura T; Hashimoto M; Morihiro T; Kubota T; Aoyama K; Kikuchi S; Nishizaki M; Kagawa S; Tazawa H; Mizuguchi H; Urata Y; Fujiwara T
    Mol Ther; 2020 Mar; 28(3):794-804. PubMed ID: 31991110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telomerase-specific oncolytic immunotherapy for promoting efficacy of PD-1 blockade in osteosarcoma.
    Mochizuki Y; Tazawa H; Demiya K; Kure M; Kondo H; Komatsubara T; Sugiu K; Hasei J; Yoshida A; Kunisada T; Urata Y; Kagawa S; Ozaki T; Fujiwara T
    Cancer Immunol Immunother; 2021 May; 70(5):1405-1417. PubMed ID: 33151368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53-armed oncolytic virotherapy induces abscopal effect in osteosarcoma by promoting immunogenic cell death.
    Demiya K; Tazawa H; Kondo H; Kure M; Mochizuki Y; Komatsubara T; Yoshida A; Uotani K; Hasei J; Fujiwara T; Kunisada T; Urata Y; Kagawa S; Ozaki T; Fujiwara T
    Mol Ther Oncol; 2024 Sep; 32(3):200845. PubMed ID: 39108499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term activation of anti-tumor immunity in pancreatic cancer by a p53-expressing telomerase-specific oncolytic adenovirus.
    Hashimoto M; Kuroda S; Kanaya N; Kadowaki D; Yoshida Y; Sakamoto M; Hamada Y; Sugimoto R; Yagi C; Ohtani T; Kumon K; Kakiuchi Y; Yasui K; Kikuchi S; Yoshida R; Tazawa H; Kagawa S; Yagi T; Urata Y; Fujiwara T
    Br J Cancer; 2024 Apr; 130(7):1187-1195. PubMed ID: 38316993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Telomerase-Specific Oncolytic Adenovirus Expressing p53 Gene Stimulating CD8+ Memory T Cells in Pancreatic Cancer].
    Hashimoto M; Kuroda S; Kanaya N; Kakiuchi Y; Kikuchi S; Tazawa H; Kagawa S; Urata Y; Fujiwara T
    Gan To Kagaku Ryoho; 2022 Oct; 49(10):1127-1129. PubMed ID: 36281608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual programmed cell death pathways induced by p53 transactivation overcome resistance to oncolytic adenovirus in human osteosarcoma cells.
    Hasei J; Sasaki T; Tazawa H; Osaki S; Yamakawa Y; Kunisada T; Yoshida A; Hashimoto Y; Onishi T; Uno F; Kagawa S; Urata Y; Ozaki T; Fujiwara T
    Mol Cancer Ther; 2013 Mar; 12(3):314-25. PubMed ID: 23315976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression.
    Nelson A; Gebremeskel S; Lichty BD; Johnston B
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35246474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model.
    Wang R; Chen J; Wang W; Zhao Z; Wang H; Liu S; Li F; Wan Y; Yin J; Wang R; Li Y; Zhang C; Zhang H; Cao Y
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression.
    Yamasaki Y; Tazawa H; Hashimoto Y; Kojima T; Kuroda S; Yano S; Yoshida R; Uno F; Mizuguchi H; Ohtsuru A; Urata Y; Kagawa S; Fujiwara T
    Eur J Cancer; 2012 Sep; 48(14):2282-91. PubMed ID: 22244827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experimental Evolution Generates Novel Oncolytic Vesicular Stomatitis Viruses with Improved Replication in Virus-Resistant Pancreatic Cancer Cells.
    Seegers SL; Frasier C; Greene S; Nesmelova IV; Grdzelishvili VZ
    J Virol; 2020 Jan; 94(3):. PubMed ID: 31694943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma.
    Fitzgerald AA; Wang S; Agarwal V; Marcisak EF; Zuo A; Jablonski SA; Loth M; Fertig EJ; MacDougall J; Zhukovsky E; Trivedi S; Bhatia D; O'Neill V; Weiner LM
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34737215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncolytic Virus-Mediated Targeting of the ERK Signaling Pathway Inhibits Invasive Propensity in Human Pancreatic Cancer.
    Koujima T; Tazawa H; Ieda T; Araki H; Fushimi T; Shoji R; Kuroda S; Kikuchi S; Yoshida R; Umeda Y; Teraishi F; Urata Y; Mizuguchi H; Fujiwara T
    Mol Ther Oncolytics; 2020 Jun; 17():107-117. PubMed ID: 32322667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer.
    Sun F; Guo ZS; Gregory AD; Shapiro SD; Xiao G; Qu Z
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional remodeling of intraperitoneal macrophages by oncolytic adenovirus restores anti-tumor immunity for peritoneal metastasis of gastric cancer.
    Tabuchi M; Kikuchi S; Tazawa H; Okura T; Ogawa T; Mitsui E; Une Y; Kuroda S; Sato H; Noma K; Kagawa S; Ohara T; Ohtsuka J; Ohki R; Urata Y; Fujiwara T
    Mol Ther Oncol; 2024 Jun; 32(2):200806. PubMed ID: 38745748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relaxin-expressing oncolytic adenovirus induces remodeling of physical and immunological aspects of cold tumor to potentiate PD-1 blockade.
    Jung BK; Ko HY; Kang H; Hong J; Ahn HM; Na Y; Kim H; Kim JS; Yun CO
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32753544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CF33-hNIS-antiPDL1 virus primes pancreatic ductal adenocarcinoma for enhanced anti-PD-L1 therapy.
    Zhang Z; Yang A; Chaurasiya S; Park AK; Lu J; Kim SI; Warner SG; Yuan YC; Liu Z; Han H; Von Hoff D; Fong Y; Woo Y
    Cancer Gene Ther; 2022 Jun; 29(6):722-733. PubMed ID: 34108669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone and Soft-Tissue Sarcoma: A New Target for Telomerase-Specific Oncolytic Virotherapy.
    Tazawa H; Hasei J; Yano S; Kagawa S; Ozaki T; Fujiwara T
    Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32085583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.